Related Experiment Video

Updated: Aug 14, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers

Kübra Canaslan1, Özge Yetginoğlu2, Yasuhiro Tsutani3

  • 1Department of Medical Oncology, Mehmet Akif İnan Research and Training Hospital, Şanlıurfa 63040, Türkiye.

International Journal of Molecular Sciences
|August 13, 2026
PubMed

Insights

Thymic epithelial tumors (TETs) show genomic alterations and high PD-L1 expression, but advances in targeted therapies and immunotherapies are limited. Overcoming barriers like trial scarcity and cost is crucial for precision oncology in TETs.

Area of Science:

  • Oncology
  • Thoracic Malignancies
  • Precision Medicine

Background:

  • Thymic epithelial tumors (TETs) are rare thoracic malignancies with limited treatment progress.
  • Genomic profiling reveals heterogeneity and high PD-L1 expression, especially in thymic carcinoma.
  • Few targeted therapies or immunotherapies have gained regulatory approval for TETs.

Purpose of the Study:

  • To review current knowledge on TET heterogeneity and genomic landscape.
  • To evaluate clinical evidence for targeted agents and immune checkpoint inhibitors.
  • To examine emerging biomarkers and discuss barriers to precision oncology in TETs.

Main Methods:

  • Mini-review synthesizing current literature on TETs.
  • Evaluation of clinical trial data for targeted therapies and immunotherapies.
  • Analysis of genomic, immunophenotypic, and biomarker data.

Main Results:

  • Recurrent genomic alterations and high PD-L1 expression are identified in TETs.
  • Significant barriers exist for precision oncology, including implementation challenges, trial scarcity, and safety concerns.
  • Translational hurdles for novel therapies like antibody-drug conjugates and cellular therapies are significant.

Conclusions:

  • Precision therapeutics for TETs face substantial challenges, including biomarker validation, trial design, and cost.
  • Addressing these barriers is essential for developing safe and equitable treatments.
  • Strategic paths forward are needed to advance precision oncology for thymic epithelial tumors.
Keywords:
antibody–drug conjugatesctDNAgenomic alterationsprecision oncologytargeted therapythymic epithelial tumors

More Related Videos

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...